KDR and hepatocellular carcinoma: A novel set of quinazolin-4 (3H)-ones was also conceptualized, synthesized with the intention of functioning as inhibitors of VEGFR-2 [52], and subsequently assessed for their efficacy in impeding the proliferation of hepatocellular carcinoma, specifically targeting the HepG-2 cell line.